6DE9

mitoNEET bound to furosemide

6DE9 の概要

• エントリーDOI: 10.2210/pdb6de9/pdb
• 分子名称: CDGSH iron-sulfur domain-containing protein 1, FE2/S2 (INORGANIC) CLUSTER, 5-(AMINOSULFONYL)-4-CHLORO-2-[(2-FURYLMETHYL)AMINO]BENZOIC ACID, ... (4 entities in total)
• 機能のキーワード: mitoneet, fes, furosemide, metal binding protein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 9685.17

構造登録者

Robart, A.R.,Geldenhuys, W.J. (登録日: 2018-05-11, 公開日: 2019-05-15, 最終更新日: 2023-10-11)

主引用文献

Geldenhuys, W.J.,Long, T.E.,Saralkar, P.,Iwasaki, T.,Nunez, R.A.A.,Nair, R.R.,Konkle, M.E.,Menze, M.A.,Pinti, M.V.,Hollander, J.M.,Hazlehurst, L.A.,Robart, A.R.
Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand.
Commun Chem, 2:-, 2019

PubMed Abstract: MitoNEET (gene ) is a mitochondrial outer membrane [2Fe-2S] protein and is a potential drug target in several metabolic diseases. Previous studies have demonstrated that mitoNEET functions as a redox-active and pH-sensing protein that regulates mitochondrial metabolism, although the structural basis of the potential drug binding site(s) remains elusive. Here we report the crystal structure of the soluble domain of human mitoNEET with a sulfonamide ligand, furosemide. Exploration of the high-resolution crystal structure is used to design mitoNEET binding molecules in a pilot study of molecular probes for use in future development of mitochondrial targeted therapies for a wide variety of metabolic diseases, including obesity, diabetes and neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

PubMed: 32382661
DOI: 10.1038/s42004-019-0172-x

実験手法

X-RAY DIFFRACTION (1.95 Å)